Abstract
Involvement of sensitive or challenging body areas is an important treatment consideration since patients with psoriasis in these areas can have disproportionately greater burden of disease. We assess comprehensive clearance by measuring the ability of ixekizumab to achieve complete skin clearance (PASI 100) up to 5 years when multiple challenging body areas (scalp, nails, palmoplantar [pp] regions) are involved. Data were integrated from UNCOVER-1 (NCT01474512) and UNCOVER-2 (NCT01597245) trials for patients with psoriasis treated with ixekizumab per label dosing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
